Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 6, 2017. The document serves as a transaction notification regarding a specific equity award to a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Award of Ordinary Shares under the 2009 Share Value Plan |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 11,060 shares |
| Price per Share | £15.135 |
| Transaction Date | September 5, 2017 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a single, isolated equity award event.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is limited to the statutory notification of the share award.
Key Facts for Investor Verification
- The transaction involved an award of 11,060 ordinary shares to Mrs. V A Whyte, SVP & Company Secretary.
- The award was made under the Company's 2009 Share Value Plan.
- The transaction price was £15.135 per share, executed on September 5, 2017.
- This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.